369 related articles for article (PubMed ID: 20010484)
1. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
Saleem A; Tristram A; Fiander A; Hibbitts S
Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
3. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
4. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccines versus cervical cancer screening.
Stanley M
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
[TBL] [Abstract][Full Text] [Related]
6. Advances in cervical cancer screening and human papillomavirus vaccines.
Feeley C
J Br Menopause Soc; 2006 Mar; 12(1):19-23. PubMed ID: 16513018
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus genotypes in cervical lesions and vaccination challenges in China.
Xu QX; Zhang ZY
Asian Pac J Cancer Prev; 2015; 16(6):2193-7. PubMed ID: 25824736
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
15. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
Friedek DA; Ekiel AM; Martirosian G
Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
[TBL] [Abstract][Full Text] [Related]
16. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
[TBL] [Abstract][Full Text] [Related]
18. HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns.
Bosch FX; Robles C
Salud Publica Mex; 2018; 60(6):612-616. PubMed ID: 30699264
[No Abstract] [Full Text] [Related]
19. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
20. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
